The proposed Center for Transport OncoPhysics (CTO) is a collaborative program among five institutions. The Principal Investigator is Dr. Mauro Ferrari (UTHSC-H) and the Senior Co-Investigator is Dr. Steven Curley (MDACC). Thus, the first overall specific aim of the proposed CTO is to construct a ?reference system? for the understanding of cancer, where the multi-dimensional ?unit vectors? are the differential laws of transport physics across a fundamental set of biobarriers as they present themselves and evolve in tumorigenesis (i.e., ?transport oncophysics?). The second overarching Specific Aim is to demonstrate the therapeutic efficacy of the novel systems and approaches developed within the CTO (multi-stage systems, nanoshuttles, carbon nanotubes, gold colloids, oral administration carriers) in the respective animal models. The proposed CTO will feature: 1. A single scientific framework (?transport oncophysics? as the differential, and biological barriers as the transport nodes);2. An integrated ?multiple multi-scale? approach (our mathematics, engineered probes, and imaging instrumentation are all multiscale, and are here employed to study the multiscale architecture of the biological barriers) reflected in shared cores and all project platforms being available to serve as cores for other projects;3. A ?dual-intent? operational approach, with the engineered transport probes used for basic discovery also being employed for the demonstration of innovative therapeutic modalities addressing unsolved clinical needs in two cancer focus cluster areas;4. An integrated choice of cancer focus and animal models. The first focus cluster is liver cancer, both primary and metastatic (Projects 1-2), the second is colorectal cancer (Projects 3), with cogent connections being the liver metastasis aspect of colorectal cancer, and the choice of unified animal models that sincerely recapitulate human diseases, under the guidance of Dr. Fidler. Further investigations that address complementary and synergistic aspects of transport onco-physics will be launched throughout the operations of the CTO by means of the Pilot Projects mechanism.

Public Health Relevance

The proposed Center for Transport Oncophysics (CTO) desires to understand the physics of mass transport within a cancer lesion and mass exchanges between cancer and surrounding host biology. Once such mechanisms are understood, the CTO hopes to develop and improve cancer diagnosis and treatment. With improved cancer diagnosis and treatment, the burden of cancer will be lessened and the eradication of cancer possible.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (O1))
Program Officer
Eljanne, Mariam
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Methodist Hospital Research Institute
United States
Zip Code
Martinez, Jonathan O; Evangelopoulos, Michael; Bhavane, Rohan et al. (2015) Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs. Curr Drug Targets 16:1582-90
Corbo, Claudia; Parodi, Alessandro; Evangelopoulos, Michael et al. (2015) Proteomic Profiling of a Biomimetic Drug Delivery Platform. Curr Drug Targets 16:1540-7
Singh, Jaykrishna; Hussain, Fazle; Decuzzi, Paolo (2015) Role of differential adhesion in cell cluster evolution: from vasculogenesis to cancer metastasis. Comput Methods Biomech Biomed Engin 18:282-92
Wang, Zhihui; Butner, Joseph D; Kerketta, Romica et al. (2015) Simulating cancer growth with multiscale agent-based modeling. Semin Cancer Biol 30:70-8
Jaganathan, Hamsa; Mitra, Sucharita; Srinivasan, Srimeenakshi et al. (2014) Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells. PLoS One 9:e91986
Yang, Yong; Wolfram, Joy; Fang, Xiaohong et al. (2014) Polyarginine induces an antitumor immune response through binding to toll-like receptor 4. Small 10:1250-4
Koshkina, Nadezhda V; Briggs, Katrina; Palalon, Flavio et al. (2014) Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment. Cancer 120:480-91
Martinez, Jonathan O; Evangelopoulos, Michael; Karun, Vivek et al. (2014) The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. Biomaterials 35:9824-32
Gonzalez-Villasana, Vianey; Rodriguez-Aguayo, Cristian; Arumugam, Thiruvengadam et al. (2014) Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther 13:2583-94
Koay, Eugene J; Truty, Mark J; Cristini, Vittorio et al. (2014) Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 124:1525-36

Showing the most recent 10 out of 114 publications